Cochrane Abstracts
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Irinotecan Chemotherapy Combined With Fluoropyrimidines Versus Irinotecan Alone for Overall Survival and Progression‐free Survival in Patients With Advanced And/or Metastatic Colorectal Cancer." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression���free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer. Accessed 30 November 2023.
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression���free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer. Accessed November 30, 2023.
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression���free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer
Irinotecan Chemotherapy Combined With Fluoropyrimidines Versus Irinotecan Alone for Overall Survival and Progression‐free Survival in Patients With Advanced And/or Metastatic Colorectal Cancer [Internet]. In: Cochrane Abstracts. [cited 2023 November 30]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression���free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
ID - 432371
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression���free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer
DB - Evidence Central
DP - Unbound Medicine
ER -
